Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Nathanson

Showing results (221-230 of 528) with videos related to

Pageof 53
Sort By:
The Journal of Clinical Endocrinology and Metabolism|September 3, 2020
Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring SystemsHeather Wachtel, Troy Hutchens, Ezra Baraban, et al.
Oncogene|April 30, 2013
MEK inhibition affects STAT3 signaling and invasion in human melanoma cell linesA Vultur, J Villanueva, C Krepler, et al.
Breast Cancer Research and Treatment|January 6, 2018
Genetic variants demonstrating flip-flop phenomenon and breast cancer risk prediction among women of African ancestryShengfeng Wang, Frank Qian, Yonglan Zheng, et al.
Cancer Genetics|May 21, 2018
Clinical germline diagnostic exome sequencing for hereditary cancer: Findings within novel candidate genes are prevalentZöe Powis, Carin R Espenschied, Holly LaDuca, et al.
British Journal of Cancer|December 3, 2019
Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutationMax M Wattenberg, Daniella Asch, Shun Yu, et al.
Cancer Research|July 18, 2008
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpressionKeiran S M Smalley, Rooha Contractor, Thiennga K Nguyen, et al.
JCO Precision Oncology|February 1, 2022
Retrospective Survival Analysis of Patients With Resected Pancreatic Ductal Adenocarcinoma and a Germline <i>BRCA</i> or <i>PALB2</i> MutationShun Yu, Parul Agarwal, Ronac Mamtani, et al.
Molecular Cancer Therapeutics|July 5, 2019
<i>In Vivo</i> ERK1/2 Reporter Predictively Models Response and Resistance to Combined BRAF and MEK Inhibitors in MelanomaIleine M Sanchez, Timothy J Purwin, Inna Chervoneva, et al.
The Journal of Investigative Dermatology|May 12, 2020
Targeting PHGDH Upregulation Reduces Glutathione Levels and Resensitizes Resistant NRAS-Mutant Melanoma to MAPK Kinase InhibitionMai Q Nguyen, Jessica L F Teh, Timothy J Purwin, et al.
Cancer|November 21, 2012
Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancerSusan M Domchek, Komal Jhaveri, Sujata Patil, et al.
Pageof 53

Showing results (221-230 of 528) with videos related to

Sort By:
Pageof 53
The Journal of Clinical Endocrinology and Metabolism|September 3, 2020
Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring SystemsHeather Wachtel, Troy Hutchens, Ezra Baraban, et al.
Oncogene|April 30, 2013
MEK inhibition affects STAT3 signaling and invasion in human melanoma cell linesA Vultur, J Villanueva, C Krepler, et al.
Breast Cancer Research and Treatment|January 6, 2018
Genetic variants demonstrating flip-flop phenomenon and breast cancer risk prediction among women of African ancestryShengfeng Wang, Frank Qian, Yonglan Zheng, et al.
Cancer Genetics|May 21, 2018
Clinical germline diagnostic exome sequencing for hereditary cancer: Findings within novel candidate genes are prevalentZöe Powis, Carin R Espenschied, Holly LaDuca, et al.
British Journal of Cancer|December 3, 2019
Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutationMax M Wattenberg, Daniella Asch, Shun Yu, et al.
Cancer Research|July 18, 2008
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpressionKeiran S M Smalley, Rooha Contractor, Thiennga K Nguyen, et al.
JCO Precision Oncology|February 1, 2022
Retrospective Survival Analysis of Patients With Resected Pancreatic Ductal Adenocarcinoma and a Germline <i>BRCA</i> or <i>PALB2</i> MutationShun Yu, Parul Agarwal, Ronac Mamtani, et al.
Molecular Cancer Therapeutics|July 5, 2019
<i>In Vivo</i> ERK1/2 Reporter Predictively Models Response and Resistance to Combined BRAF and MEK Inhibitors in MelanomaIleine M Sanchez, Timothy J Purwin, Inna Chervoneva, et al.
The Journal of Investigative Dermatology|May 12, 2020
Targeting PHGDH Upregulation Reduces Glutathione Levels and Resensitizes Resistant NRAS-Mutant Melanoma to MAPK Kinase InhibitionMai Q Nguyen, Jessica L F Teh, Timothy J Purwin, et al.
Cancer|November 21, 2012
Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancerSusan M Domchek, Komal Jhaveri, Sujata Patil, et al.
Pageof 53